TY - JOUR
T1 - Single subcutaneous dosing of cefovecin in rhesus monkeys (Macaca mulatta)
T2 - a pharmacokinetic study
AU - Bakker, J.
AU - Thuesen, Line Risager
AU - Braskamp, G.
AU - Skaanild, Mette Tingleff
AU - Ouwerling, B.
AU - Langermans, J.A.M.
AU - Bertelsen, Mads Frost
N1 - © 2011 Blackwell Publishing Ltd.
PY - 2011/10
Y1 - 2011/10
N2 - Cefovecin is a third-generation cephalosporin approved for antibacterial treatment with a 14-day dosing interval in dogs and cats. This antibiotic may also be useful for zoo and wildlife veterinary medicine, because of its broad spectrum and long duration of activity. The aim of the study was to determine whether cefovecin is a suitable antibiotic to prevent skin wound infection in rhesus monkeys. Therefore, the pharmacokinetics (PK) of cefovecin after a single subcutaneous injection at 8mg/kg bodyweight in four rhesus monkeys (Macaca mulatta) and sensitivity of bacterial isolates from fresh skin wounds were determined. After administration, blood, urine, and feces were collected, and concentrations of cefovecin were determined. Further, the minimum inhibitory concentrations (MIC) for bacteria isolated from fresh skin wounds of monkeys during a health control program were determined. The mean maximum plasma concentration (C max) of cefovecin was 78μg/mL and was achieved after 57min. The mean apparent long elimination half-life (t1/2) was 6.6h and excretion occurred mainly via urine. The MIC for the majority of the bacteria examined was >100μg/mL. The PK of cefovecin in rhesus monkeys is substantially different than for dogs and cats. Cefovecin rapidly reached C max which however was lower than most of the MIC levels and with a very short t1/2. Therefore, cefovecin is not recommended for treating skin wounds in rhesus monkeys.
AB - Cefovecin is a third-generation cephalosporin approved for antibacterial treatment with a 14-day dosing interval in dogs and cats. This antibiotic may also be useful for zoo and wildlife veterinary medicine, because of its broad spectrum and long duration of activity. The aim of the study was to determine whether cefovecin is a suitable antibiotic to prevent skin wound infection in rhesus monkeys. Therefore, the pharmacokinetics (PK) of cefovecin after a single subcutaneous injection at 8mg/kg bodyweight in four rhesus monkeys (Macaca mulatta) and sensitivity of bacterial isolates from fresh skin wounds were determined. After administration, blood, urine, and feces were collected, and concentrations of cefovecin were determined. Further, the minimum inhibitory concentrations (MIC) for bacteria isolated from fresh skin wounds of monkeys during a health control program were determined. The mean maximum plasma concentration (C max) of cefovecin was 78μg/mL and was achieved after 57min. The mean apparent long elimination half-life (t1/2) was 6.6h and excretion occurred mainly via urine. The MIC for the majority of the bacteria examined was >100μg/mL. The PK of cefovecin in rhesus monkeys is substantially different than for dogs and cats. Cefovecin rapidly reached C max which however was lower than most of the MIC levels and with a very short t1/2. Therefore, cefovecin is not recommended for treating skin wounds in rhesus monkeys.
U2 - 10.1111/j.1365-2885.2010.01265.x
DO - 10.1111/j.1365-2885.2010.01265.x
M3 - Journal article
C2 - 21323930
SN - 0140-7783
VL - 34
SP - 464
EP - 468
JO - Journal of Veterinary Pharmacology and Therapeutics
JF - Journal of Veterinary Pharmacology and Therapeutics
IS - 5
ER -